ONK THERAPEUTICS
ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of off-the-shelf, optimally engineered natural killer (NK) cell therapies targeting both hematological malignancies and solid tumors.
ONK THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2009-01-01
Address:
Barna, Galway, Ireland
Country:
Ireland
Website Url:
http://www.onktherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
21.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Euro Contact Form 7 WordPress 5.9 LinkedIn Follow Company Plugin
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Atara Biotherapeutics
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
VYNE Therapeutics
VYNE Therapeutics is a clinical late-stage biopharmaceutical company developing treatments associated with dermatologic conditions.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series A - ONK Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Series A - ONK Therapeutics
ALSHC
ALSHC investment in Series A - ONK Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-03 | XNK Therapeutics appoints Markus Thor as Chief Business Officer |
Official Site Inspections
http://www.onktherapeutics.com Semrush global rank: 4.76 M Semrush visits lastest month: 1.94 K
- Host name: pemlinng060.blacknight.com
- IP address: 78.153.210.6
- Location: Ireland
- Latitude: 53.3472
- Longitude: -6.2439
- Timezone: Europe/Dublin
More informations about "ONK Therapeutics"
About – ONK Therapeutics
Proprietary platform. The company’s proprietary NK cell therapy platform is based on a dual-targeted construct, combining a chimeric antigen receptor (CAR) targeting a known tumor …See details»
ONK Therapeutics - Crunchbase Company Profile
Contact Email [email protected] ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of off-the-shelf, optimally engineered natural killer (NK) cell therapies targeting both …See details»
ONK Therapeutics - LinkedIn
ONK Therapeutics | 5,188 followers on LinkedIn. Pioneering optimally engineered NK cell therapies to cure patients with cancer. | ONK Therapeutics, is an innovative cell therapy company dedicated ...See details»
ONK Therapeutics and NAYA Biosciences Announce Research …
Dec 6, 2023 About ONK Therapeutics – www.onktherapeutics.com. ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of optimally …See details»
ONK Therapeutics Announces $21.5M Series A …
Jan 6, 2022 About ONK Therapeutics – www.onktherapeutics.com. ... ONK Therapeutics on LinkedIn (organization) Contacts. International Sue Charles Charles Consultants +44 7968 726585 [email protected].See details»
ONK Therapeutics Company Overview, Contact Details
Jan 6, 2022 ONK Therapeutics Limited hired Bruce McCreedy as Chief Scientific Officer on Jun 12th '22. Bruce McCreedy Ph.D. joins the Executive Leadership Team as Chief Scientific …See details»
ONK Therapeutics - Craft
ONK Therapeutics is a company that develops natural killer cell-based therapies intended to target blood cancer with unmet needs. Its technology offers optimization of natural-killer cells …See details»
ONK Therapeutics Boosts Drug Development Experience and
Dec 6, 2022 Follow us on Twitter @ONKTherapeutics and LinkedIn. International Sue Charles, Charles Consultants - +44 7968 726585 [email protected]. IrelandSee details»
ONK Therapeutics Strengthens its Cell Therapy
Mar 18, 2021 ONK Therapeutics – www.onktherapeutics.com ONK Therapeutics Ltd is an innovative cell therapy company dedicated to developing the next generation of ‘off-the-shelf’, dual-targeted NK cell ...See details»
ONK Therapeutics and NAYA Biosciences Announce Research
Dec 6, 2023 About ONK Therapeutics – www.onktherapeutics.com ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of optimally …See details»
ONK Therapeutics - VentureRadar
Similar Companies: Catamaran Bio USA Privately Held Catamaran is developing transformative off-the-shelf CAR-NK cell therapies. We are driven to realize the full potential of cell therapy by …See details»
Intellia and ONK Therapeutics Announce Collaboration to Advance ...
Feb 15, 2022 Follow us on Twitter @ONKTherapeutics and LinkedIn. Forward-Looking Statements. This press release contains forward-looking statements within the meaning of the …See details»
ONK Therapeutics Presents Promising In-Vivo Data of its
Aug 29, 2022 GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)-- ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer (NK) cell …See details»
Maximizing synergy and mitigating resistance: novel dual-targeted ...
With its breakthrough dual-targeted natural killer cell therapy platform, ONK Therapeutics is creating its own pipeline of cell therapy candidates, and seeks to further unlock its potential ...See details»
ONK Therapeutics Presents Promising - Business Wire
Aug 29, 2022 First in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy ; Data showed potent anti-tumor activity in-vitro and in-vivo of cord-derived …See details»
ONK Therapeutics Announces $21.5M Series A Financing to …
Jan 6, 2022 Follow us on Twitter @ONKTherapeutics and LinkedIn. International. Sue Charles, Charles Consultants – +44 7968 726585 [email protected]. Ireland. Ray Gordon, …See details»
Intellia and ONK Therapeutics Announce Collaboration to Advance ...
Feb 15, 2022 ONK is responsible for the research, clinical development and commercialization of engineered NK cell therapies derived from collaboration. Intellia to receive global co …See details»
ONK Therapeutics Presents Promising In-Vivo Data of its …
Aug 30, 2022 First in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy; Data showed potent anti-tumor activity in-vitro and in-vivo of cord-derived …See details»
ONK Therapeutics Named Most Promising Company in BioSpace’s …
Jan 4, 2023 Galway, Ireland and San Diego, USA, 4 January 2023 – ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer (NK) cell …See details»